Drug Research
BioInvent’s BI-1206 could improve treatment in several cancers
Alexander Eggermont, MD, PhD, Chief Scientific Officer at the Princess Máxima Center and renowned expert in immunotherapy showcased the broad potential of BI-1206 in enhancing checkpoint inhibitors in solid cancers in a KOL event hosted by BioInvent on July...
Drug Research
Catalent Biologics to Invest $30 Million to Create European Clinical Manufacturing Center of Excellence in France
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it plans to invest $30 million (€27 million) at its facility in Limoges,...
Drug Research
GSK and CureVac announce strategic mRNA technology collaboration
GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA...
Drug Research
CMIC Group Establishes a New Biologic Contract Development and Manufacturing Business in Japan
CMIC HOLDINGS Co., Ltd. announced the establishment of CMIC BIO Co., Ltd. (hereafter CMIC BIO), a fully-owned subsidiary that offers Contract Development and Manufacturing Organization (hereinafter CDMO) services for biopharmaceutical drug substance. CMIC Bio has a single-use facility in...
Drug Research
CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidate
CEPI, the Coalition for Epidemic Preparedness Innovations, announced the expansion of its partnership with Sichuan Clover Biopharmaceuticals, Inc to rapidly advance the development and manufacture of Clover’s protein-based COVID-19 S-Trimer vaccine candidate, which is based on Clover’s proprietary Trimer-Tag©...
Drug Research
Samsung Biologics and ImmuneOncia sign multi-product development and manufacturing agreement
Samsung Biologics and ImmuneOncia Therapeutics held a signing ceremony for a contract to develop and manufacture five candidate molecules, expanding upon the two companies existing CDO partnership first established in 2018.
“As we already have a track record of successful...
Drug Research
Biophore India gets DCGI nod to manufacture COVID drug Favipiravir API
Biophore India Pharmaceuticals, a Hyderabad-based firm, has received license from the Drug Controller General of India (DCGI) to manufacture Favipiravir, an active pharmaceutical ingredient (API), used in the finished formulation to treat mild to moderate COVID-19 cases. Besides DCGI’s...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read